DK1902141T3 - ADAMTS 13-holdige sammensætninger med thrombolytisk virkning - Google Patents

ADAMTS 13-holdige sammensætninger med thrombolytisk virkning

Info

Publication number
DK1902141T3
DK1902141T3 DK06754405.6T DK06754405T DK1902141T3 DK 1902141 T3 DK1902141 T3 DK 1902141T3 DK 06754405 T DK06754405 T DK 06754405T DK 1902141 T3 DK1902141 T3 DK 1902141T3
Authority
DK
Denmark
Prior art keywords
thrombus
adamts
containing compositions
thrombolytic effect
adamts13
Prior art date
Application number
DK06754405.6T
Other languages
English (en)
Inventor
Denisa Wagner
Anil Kumar Chauhan
Friedrich Scheiflinger
Barbara Plaimauer
Original Assignee
Baxter Int
Baxter Healthcare Sa
Cbr Inst For Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Cbr Inst For Biomedical Res filed Critical Baxter Int
Application granted granted Critical
Publication of DK1902141T3 publication Critical patent/DK1902141T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK06754405.6T 2005-06-17 2006-06-16 ADAMTS 13-holdige sammensætninger med thrombolytisk virkning DK1902141T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69192705P 2005-06-17 2005-06-17
US72932305P 2005-10-21 2005-10-21
US77126506P 2006-02-07 2006-02-07
PCT/EP2006/005800 WO2006133955A1 (en) 2005-06-17 2006-06-16 Adamts13-comprising compositions having thrombolytic activity

Publications (1)

Publication Number Publication Date
DK1902141T3 true DK1902141T3 (da) 2012-05-07

Family

ID=36956096

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06754405.6T DK1902141T3 (da) 2005-06-17 2006-06-16 ADAMTS 13-holdige sammensætninger med thrombolytisk virkning

Country Status (9)

Country Link
US (4) US20070015703A1 (da)
EP (1) EP1902141B1 (da)
AT (1) ATE544866T1 (da)
AU (1) AU2006257073B2 (da)
CA (1) CA2606351C (da)
DK (1) DK1902141T3 (da)
ES (1) ES2382104T3 (da)
PL (1) PL1902141T3 (da)
WO (1) WO2006133955A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK1902141T3 (da) 2005-06-17 2012-05-07 Baxter Int ADAMTS 13-holdige sammensætninger med thrombolytisk virkning
FR2918375B1 (fr) 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
AU2009246603B8 (en) * 2008-05-12 2015-08-13 Children's Medical Center Corporation von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction
NZ592905A (en) * 2008-10-27 2012-11-30 Baxter Int Models of thrombotic thrombocytopenic purpura and methods of use thereof
ES2685503T3 (es) 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
JP5411582B2 (ja) * 2009-06-02 2014-02-12 一般財団法人化学及血清療法研究所 Ａｄａｍｔｓ１３による細胞移植増強補助剤
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
EP4218797B9 (en) * 2009-09-21 2025-04-30 Takeda Pharmaceutical Company Limited Stabilized liquid and lyophilized adamts13 formulations
EP3150635A3 (en) * 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK2694108T3 (da) 2011-04-08 2018-08-20 Univ Leicester Fremgangsmåder til behandling af lidelser associeret med masp-2-afhængig komplementaktivering
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
CN105991563B (zh) * 2015-02-05 2020-07-03 阿里巴巴集团控股有限公司 一种保护敏感数据安全的方法、装置及三方服务系统
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
CN116059236A (zh) 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN108463729B (zh) 2016-01-08 2021-03-19 国立大学法人京都大学 以adamts13作为主要成分的诊断药和药品
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
KR20260009385A (ko) 2017-08-25 2026-01-19 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
US12661390B2 (en) * 2019-10-04 2026-06-23 The Children's Medical Center Corporation ADAMTS13 treatment to enhance graft survival
EP4127158A2 (en) 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
CN115835904A (zh) 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法
IL302984A (en) * 2020-11-18 2023-07-01 Green Cross Corp Adamts13 variant having increased escaping rate or activity against autoantibody
EP4592322A4 (en) * 2022-09-23 2026-08-05 Chuang Woei Jer Fusion protein targeting alpha(IIB)beta3 integrin and containing a tissue plasminogen activator or a variant thereof, and its use
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082218A (da) * 1973-11-10 1975-07-03
US4791138A (en) * 1983-12-14 1988-12-13 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US20030073115A1 (en) * 2002-09-16 2003-04-17 Shyam Ramakrishnan Regulation of human galanin receptor-like g protein coupled receptor
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
DK1902141T3 (da) 2005-06-17 2012-05-07 Baxter Int ADAMTS 13-holdige sammensætninger med thrombolytisk virkning

Also Published As

Publication number Publication date
EP1902141B1 (en) 2012-02-08
WO2006133955A1 (en) 2006-12-21
US20220002703A1 (en) 2022-01-06
US20190161746A1 (en) 2019-05-30
AU2006257073A1 (en) 2006-12-21
US10233436B2 (en) 2019-03-19
EP1902141A1 (en) 2008-03-26
US20070015703A1 (en) 2007-01-18
US11124787B2 (en) 2021-09-21
AU2006257073B2 (en) 2011-08-04
ATE544866T1 (de) 2012-02-15
WO2006133955A8 (en) 2007-11-29
PL1902141T3 (pl) 2012-12-31
CA2606351A1 (en) 2006-12-21
HK1118579A1 (en) 2009-02-13
US20130136732A1 (en) 2013-05-30
CA2606351C (en) 2016-12-13
ES2382104T3 (es) 2012-06-05

Similar Documents

Publication Publication Date Title
PL1902141T3 (pl) Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
EP2493507A4 (en) AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
WO2008057458A3 (en) Antagonists of pcsk9
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MY155961A (en) Chemical compounds 251
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MX2009005527A (es) Metodos para el tratamiento de hipercolesterolemia.
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen